Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase III OPTiM trial.
| Image |  |
|---|---|
| Description | scientific article published on 6 November 2014 |
| Author/s |
author: Igor Puzanov |
| Publication date | November 6, 2014 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |